Research programme: USP15 protein inhibitors - Corbin Therapeutics/University of Dundee

Latest Information Update: 08 Jun 2017

Price : ^*

* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

Originator Corbin Therapeutics; University of Dundee
Class Anti-inflammatories; Small molecules
Mechanism of Action USP15 protein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Research Inflammation

Most Recent Events

22 May 2017 University of Dundee and Corbin Therapeutics agree to co-develop USP15 protein inhibitors for Inflammation
22 May 2017 Early research in Inflammation in Scotland, Canada (unspecified route)

Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Login with a username/password associated to an account with a valid subscription
Contact your organization’s admin about adding this content to your AdisInsight subscription
Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.